10-Q · May 13, 2026
Adicet Bio, Inc. reported a net loss improvement of 28% YoY in Q1 2026, with a diluted EPS of -$1.88 compared to -$4.96 in Q1 2025. Total operating expenses decreased by 28% to $21.57 million as R&D and G&A expenses…
Earnings analysis · 10-K
ACET earnings analysis
Filed May 20, 2026 · Our reading of the company's report
The latest report
Adicet Bio, Inc. reported a decline in operational performance for the fiscal year ended December 31, 2025, showcasing substantial losses, with a diluted EPS of -$1.91 in Q4 2025, down from -$5.44 in Q2 2025. The…
Read full summary
Adicet Bio, Inc. reported a decline in operational performance for the fiscal year ended December 31, 2025, showcasing substantial losses, with a diluted EPS of -$1.91 in Q4 2025, down from -$5.44 in Q2 2025. The company continues to face challenges in revenue generation; however, it is optimistic about advancements in its clinical pipeline, which could provide avenues for future growth.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.91
What stood out
-
Decline in Losses
The diluted EPS improved sequentially to -$1.91 in Q4 2025 from -$5.44 in Q2 2025, indicating potential operational efficiencies.
-
Cost Reductions
Total operating expenses decreased significantly, contributing to the improved loss figures.
-
Strong Market Position
As of June 30, 2025, the company's market value stood at approximately $50.5 million, reflecting ongoing investor interest despite losses.
What to watch
-
Ongoing Financial Losses
The company reported substantial losses throughout 2025, with diluted EPS ranging from -5.01 to -1.91 over the quarters.
-
Revenue Generation Challenges
Adicet reported zero revenue in Q4 2025 and continues to face significant hurdles in establishing a reliable revenue stream.
-
Regulatory Risks
Ongoing regulatory risks related to clinical trials, which could impede the drug approval process.
Management's outlook
Management has not provided specific numeric guidance for future periods, maintaining an outlook of ongoing operational financing needs.
Earlier filings 4
10-K · March 12, 2026
Adicet positions itself as a leader in allogeneic gamma delta CAR‑T therapies with a prioritized autoimmune program (prula‑cel) and a next‑generation oncology candidate (ADI‑212). The 10‑K highlights positive early…
10-Q · May 6, 2025
Adicet reported a Q1 2025 net loss per share of $(0.31), beating the consensus estimate of $(0.34) by $0.03. The company ended the quarter with $28,133 in cash and cash equivalents and $122,306 in short-term treasury…
10-Q · August 13, 2024
Adicet Bio reported a Q2 net loss of $29.9M (EPS -$0.33) versus a loss of $32.4M (EPS -$0.75) in Q2 2023, showing a sequential improvement in per-share loss driven by lower R&D expense and a larger share base. Cash and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.